Related Experiment Video
Updated: Jan 6, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated
Javier Armisen1, Armando Flor2, John Eriksson3
1Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Background And Aims:
Neutrophil myeloperoxidase is involved in different inflammatory diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Mitiperstat is a highly potent myeloperoxidase inhibitor. This phase 2a clinical trial evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of mitiperstat in patients with non-cirrhotic MASH.
Methods:
The study enrolled 112 adult participants with histological MASH F1-3 fibrosis and increased alanine aminotransferase (ALT) levels. Participants were randomised 1:1 to once-daily mitiperstat 5 mg or placebo. Primary and secondary endpoints were absolute and placebo-adjusted changes from baseline to week 12 in ALT and N-terminal type-III collagen propeptide (Pro-C3) levels. Exploratory endpoints included other MASH-related biomarkers.
Results:
At week 12, there were no significant changes versus placebo for ALT (+7.5%, p = 0.893) and Pro-C3 (-0.9%, p = 0.396), or any other MASH-related biomarkers. Mitiperstat was safe and well tolerated.
Conclusion:
This study does not provide proof of concept that mitiperstat 5 mg exerts an anti-inflammatory/anti-fibrotic effect in MASH.
Trial Registration:
ClincalTrials.gov identifier: NCT05638737.
More Related Videos
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
Related Concept Videos
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Drug Metabolism: Phase I Reactions
Phase I Oxidative Reactions: Overview
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Metabolism: Phase II Reactions
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...